keyword
MENU ▼
Read by QxMD icon Read
search

Zika virus vaccine

keyword
https://www.readbyqxmd.com/read/28797534/current-status-of-therapeutic-and-vaccine-approaches-against-zika-virus
#1
REVIEW
Braira Wahid, Amjad Ali, Shazia Rafique, Muhammad Idrees
Zika virus (ZIKV) is a global threat because it is spreading at an alarming rate because of its wider range of transmission routes. The neuroteratogenic nature of ZIKV infection is posing serious threats to unborn lives therefore, it is necessary to develop an ideal ZIKV prophylactic or therapeutic agent urgently. Researchers are having tough time finding a treatment for ZIKV in part because of serious consequences of vaccines and drugs to unborn lives and pregnant women. However, in vitro and in vivo evaluation of therapeutic efficacy of DNA vaccine, recombinant subunit vaccine, and ZIKV purified inactivated vaccine offers hope for human protection...
August 7, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28794424/virus-like-particles-that-display-zika-virus-envelope-protein-domain-iii-induce-potent-neutralizing-immune-responses-in-mice
#2
Ming Yang, Huafang Lai, Haiyan Sun, Qiang Chen
Several Zika virus (ZIKV) vaccine candidates have recently been described which use inactivated whole virus, DNA or RNA that express the virus' Envelope (E) glycoprotein as the antigen. These were successful in stimulating production of virus-targeted antibodies that protected animals against ZIKV challenges, but their use potentially will predispose vaccinated individuals to infection by the related Dengue virus (DENV). We have devised a virus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV E protein domain III (zDIII), and shown that it can be produced quickly and easily purified in large quantities from Nicotiana benthamiana plants...
August 9, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28794181/a-neutralization-assay-for-zika-and-dengue-viruses-using-a-real-time-pcr-based-endpoint-assessment
#3
Heather L Wilson, Thomas Tran, Julian Druce, Myrielle Dupont-Rouzeyrol, Michael Catton
The global spread and infective complications of Zika virus (ZKV) and Dengue virus (DENV) have made them flaviviruses of public health concern. Serological diagnosis can be challenging due to antibody cross-reactivity, particularly in secondary flavivirus infections or when there is a history of flavivirus vaccination. The virus neutralization assay is considered to be the most specific assay for measurement of anti-flavivirus antibodies. This study describes an assay where neutralization endpoint is measured by real-time PCR, providing results within 72 hours...
August 9, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28794019/development-of-virus-like-particle-vaccine-and-reporter-assay-for-zika-virus
#4
Himanshu Garg, Melina Sedano, Gabrielle Plata, Erin B Punke, Anjali Joshi
Recent worldwide outbreaks of Zika virus (ZIKV) infection and the lack of an approved vaccine raises serious concerns regarding preparedness to combat this emerging virus. We used a Virus Like Particle (VLP) based approach to develop a vaccine and a microneutralization assay against ZIKV. Synthetic C-prM-E (Capsid-preMembrane-Envelope) gene construct of ZIKV was used to generate Reporter Virus Particles (RVPs) that package GFP reporter expressing WNV replicon. The assay was adapted to 96 well format, similar to the Plaque Reduction Neutralization Test (PRNT) and showed high reproducibility with specific detection of ZIKV neutralizing antibodies...
August 9, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28789826/zika-virus-protease-an-antiviral-drug-target
#5
REVIEW
CongBao Kang, Thomas H Keller, Dahai Luo
The recent outbreak of Zika virus (ZIKV) infection has caused global concern due to its link to severe damage to the brain development of foetuses and neuronal complications in adult patients. A worldwide research effort has been undertaken to identify effective and safe treatment and vaccination options. Among the proposed viral and host components, the viral NS2B-NS3 protease represents an attractive drug target due to its essential role in the virus life cycle. Here, we outline recent progress in studies on the Zika protease...
August 5, 2017: Trends in Microbiology
https://www.readbyqxmd.com/read/28783378/the-latest-advancements-in-zika-virus-vaccine-development
#6
Lanying Du, Yusen Zhou, Shibo Jiang
No abstract text is available yet for this article.
August 7, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28768876/monoclonal-antibodies-against-zika-virus-therapeutics-and-their-implications-for-vaccine-design
#7
Qihui Wang, Jinghua Yan, George Fu Gao
Zika virus (ZIKV) has caused global concern due to its association with neurological complications in newborns and adults. Although no approved vaccines or antivirals against ZIKV infection to date, hundreds of monoclonal antibodies (MAbs) have been developed in a short period. Here, we first present a complete picture of the ZIKV MAbs and then focus on the neutralizing mechanisms and immune hot spot uncovered through structural studies, which provide insight for therapeutics and vaccine design.
August 2, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28758019/current-trends-in-zika-vaccine-development
#8
EDITORIAL
Francisco A Lagunas-Rangel, Martha E Viveros-Sandoval, Arturo Reyes-Sandoval
The Zika virus (ZIKV) was first isolated in 1947 in Uganda. While it took 60 years for this virus to cause major outbreaks, an important shift in its ability to cause epidemics took place in the first and second decades of the this century: in 2007 in Yap Island, Micronesia, followed by French Polynesia in 2013 and, finally in 2015 and 2016, when ZIKV infections occurred throughout South America, Central America and the Caribbean, spreading rapidly to reach North America in just a single year. No licensed prophylactic vaccine is yet available but recent efforts towards the development of a vaccine have been remarkable from both the private and public sectors and include new candidate vaccines ranging from the classical live-attenuated or inactivated vaccines to more sophisticated approaches such as mRNA or genetically engineered viral platforms...
July 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/28754189/progress-and-works-in-progress-update-on-flavivirus-vaccine-development
#9
REVIEW
Matthew H Collins, Stefan W Metz
Most areas of the globe are endemic for at least one flavivirus, putting billions at risk for infection. This diverse group of viral pathogens causes a range of manifestations in humans from asymptomatic infection to hemorrhagic fever to encephalitis to birth defects and even death. Many flaviviruses are transmitted by mosquitos and have expanded in geographic distribution in recent years, with dengue virus being the most prevalent, infecting approximately 400 million people each year. The explosive emergence of Zika virus in Latin America in 2014 refocused international attention on this medically important group of viruses...
July 25, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28747174/knowledge-and-perceptions-about-zika-virus-in-a-middle-east-country
#10
Sohaila Cheema, Patrick Maisonneuve, Ingmar Weber, Luis Fernandez-Luque, Amit Abraham, Hekmat Alrouh, Javaid Sheikh, Albert B Lowenfels, Ravinder Mamtani
BACKGROUND: Zika virus, an emerging serious infectious disease, is a threat to persons living or travelling to regions where it is currently endemic, and also to contacts of infected individuals. The aim of this study was to assess knowledge about this new public health threat to persons residing in a Middle Eastern country. METHODS: We conducted a survey at several international universities in Qatar to assess knowledge and awareness about this disease. An adapted version of the survey was also conducted using online channels from Qatar...
July 26, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28742857/dna-immunisation-with-dengue-virus-e-protein-domains-i-ii-but-not-domain-iii-enhances-zika-west-nile-and-yellow-fever-virus-infection
#11
Jose L Slon Campos, Monica Poggianella, Sara Marchese, Monica Mossenta, Jyoti Rana, Francesca Arnoldi, Marco Bestagno, Oscar R Burrone
Dengue virus (DENV), the causative agent of dengue disease, is among the most important mosquito-borne pathogens worldwide. DENV is composed of four closely related serotypes and belongs to the Flaviviridae family alongside other important arthropod-borne viral pathogens such as Zika virus (ZIKV), West Nile virus (WNV) and Yellow Fever virus (YFV). After infection, the antibody response is mostly directed to the viral E glycoprotein which is composed of three structural domains named DI, DII and DIII that share variable degrees of homology among different viruses...
2017: PloS One
https://www.readbyqxmd.com/read/28742068/a-peptide-based-viral-inactivator-inhibits-zika-virus-infection-in-pregnant-mice-and-fetuses
#12
Yufeng Yu, Yong-Qiang Deng, Peng Zou, Qian Wang, Yanyan Dai, Fei Yu, Lanying Du, Na-Na Zhang, Min Tian, Jia-Nan Hao, Yu Meng, Yuan Li, Xiaohui Zhou, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Cheng-Feng Qin, Shibo Jiang, Lu Lu
Zika virus (ZIKV), a re-emerging flavivirus associated with neurological disorders, has spread rapidly to more than 70 countries and territories. However, no specific vaccines or antiviral drugs are currently available to prevent or treat ZIKV infection. Here we report that a synthetic peptide derived from the stem region of ZIKV envelope protein, designated Z2, potently inhibits infection of ZIKV and other flaviviruses in vitro. We show that Z2 interacts with ZIKV surface protein and disrupts the integrity of the viral membrane...
July 25, 2017: Nature Communications
https://www.readbyqxmd.com/read/28740150/identification-of-putative-unique-immunogenic-zikv-and-denv1-4-peptides-for-diagnostic-cellular-based-tests
#13
Aaron L Oom, Davey Smith, Kevan Akrami
Since the re-emergence of Zika virus in 2014 and subsequent association with microcephaly, much work has focused on the development of a vaccine to halt its spread throughout the world. The mosquito vector that transmits this virus is widespread and responsible for the spread of other arboviridae including Dengue. Current diagnostic methods rely on serologic testing that are complicated by cross reactivity and therefore unable to distinguish Zika from Dengue infection in the absence of virus isolation. We performed an in silico analysis to identify potential epitopes that may stimulate a unique T-lymphocyte response to distinguish prior infection with Zika or Dengue...
July 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28734519/zika-virus-infection
#14
REVIEW
Debbie-Ann T Shirley, James P Nataro
In less than 2 years since entry into the Americas, we have witnessed the emergent spread of Zika virus into large subsets of immunologically naïve human populations and then encountered the devastating effects of microcephaly and brain anomalies that can arise from in utero infection with the virus. Diagnostic evaluation and management of affected infants continues to evolve as our understanding of Zika virus rapidly advances. The development of a safe and effective vaccine holds the potential to attenuate the spread of infection and limit the impact of congenital infection...
August 2017: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/28724343/vero-cell-technology-for-rapid-development-of-inactivated-whole-virus-vaccines-for-emerging-viral-diseases
#15
P Noel Barrett, Sara J Terpening, Doris Snow, Ronald R Cobb, Otfried Kistner
Rapid development and production of vaccines against emerging diseases requires well established, validated, robust technologies to allow industrial scale production and accelerated licensure of products. Areas covered: A versatile Vero cell platform has been developed and utilized to deliver a wide range of candidate and licensed vaccines against emerging viral diseases. This platform builds on the 35 years' experience and safety record with inactivated whole virus vaccines such as polio vaccine. The current platform has been optimized to include a novel double inactivation procedure in order to ensure a highly robust inactivation procedure for novel emerging viruses...
September 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28719291/knowledge-and-prevention-practices-among-u-s-pregnant-immigrants-from-zika-virus-outbreak-areas
#16
Abbey B Berenson, Ha N Trinh, Jacqueline M Hirth, Fangjian Guo, Erika L Fuchs, Scott C Weaver
We administered an anonymous survey to assess knowledge, attitudes, and prevention practices related to the Zika virus among pregnant women residing in Texas. Multivariate logistic regression models controlling for age, race/ethnicity, education, and number of years in the United States assessed differences between women born in outbreak areas (N = 390) versus those born in the United States (N = 249). Results demonstrated that most women wanted more information on the Zika virus and desired to obtain it from their physician...
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28716913/antibody-based-assay-discriminates-zika-virus-infection-from-other-flaviviruses
#17
Angel Balmaseda, Karin Stettler, Raquel Medialdea-Carrera, Damaris Collado, Xia Jin, José Victor Zambrana, Stefano Jaconi, Elisabetta Cameroni, Saira Saborio, Francesca Rovida, Elena Percivalle, Samreen Ijaz, Steve Dicks, Ines Ushiro-Lumb, Luisa Barzon, Patricia Siqueira, David W G Brown, Fausto Baldanti, Richard Tedder, Maria Zambon, A M Bispo de Filippis, Eva Harris, Davide Corti
Zika virus (ZIKV) is a mosquito-borne flavivirus that emerged recently as a global health threat, causing a pandemic in the Americas. ZIKV infection mostly causes mild disease, but is linked to devastating congenital birth defects and Guillain-Barré syndrome in adults. The high level of cross-reactivity among flaviviruses and their cocirculation has complicated serological approaches to differentially detect ZIKV and dengue virus (DENV) infections, accentuating the urgent need for a specific and sensitive serological test...
August 1, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28716884/which-dengue-vaccine-approach-is-the-most-promising-and-should-we-be-concerned-about-enhanced-disease-after-vaccination-the-challenges-of-a-dengue-vaccine
#18
Gavin Screaton, Juthathip Mongkolsapaya
A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellow fever, progress has been slow. In this review, we describe progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of a highly dynamic structurally flexible dengue virus particle. Finally, we review recent evidence for cross-reactivity between antibody responses to Zika and dengue viruses, which may further complicate the development of broadly protective dengue virus vaccines...
July 17, 2017: Cold Spring Harbor Perspectives in Biology
https://www.readbyqxmd.com/read/28711586/achieving-safe-effective-and-durable-zika-virus-vaccines-lessons-from-dengue
#19
REVIEW
Scott B Halstead
Newly proposed candidate Zika virus vaccines might or might not succeed in raising safe, effective, and durable protection against human Zika virus infections or syndromes. Analyses of a clinically tested and licensed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced dengue infections suggest that poor T-cell immunity might have contributed to protection failure. Because of the similarity of Zika and dengue viruses, an analogous unwanted outcome might occur with some Zika virus vaccine designs...
July 12, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28710796/plant-produced-zika-virus-envelope-protein-elicits-neutralizing-immune-responses-that-correlate-with-protective-immunity-against-zika-virus-in-mice
#20
Ming Yang, Haiyan Sun, Huafang Lai, Jonathan Hurtado, Qiang Chen
The global Zika virus (ZIKV) outbreak and its link to fetal and newborn microcephaly and severe neurological complications in adults call for the urgent development of ZIKV vaccines. In response, we developed a subunit vaccine based on the ZIKV envelope (E) protein and investigated its immunogenicity in mice. Transient expression of ZIKV E (zE) resulted in its rapid accumulation in leaves of Nicotiana benthamiana plants. Biochemical analysis revealed that plant-produced ZIKV E (PzE) exhibited specific binding to a panel of monoclonal antibodies that recognize various zE conformational epitopes...
July 15, 2017: Plant Biotechnology Journal
keyword
keyword
115642
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"